To the Copenhagen Stock Exchange Announcement No. 19-07 / Copenhagen, 1 June 2007 Report on share capital and share rights for TopoTarget A/S According to Executive Order no. 226 of 15 March 2007 regarding issuers' obligations, we hereby notify that the Company's share capital per 1 June 2007 is nominal DKK 45,706,480 divided into shares of DKK 1 each. Each share of DKK 1 carries one vote. Total share rights are 45,706,480 All shares are ordinary shares and no shares carry special rights. TopoTarget A/S Background information About TopoTarget TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regula-tors (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclini-cal drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to www.topotarget.com.